Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Belantamab mafodotin in combination with pembrolizumab for treating cancer

A technology for pembrolizumab and cancer, applied in drug combinations, antibody medical components, anti-receptor/cell surface antigen/cell surface determinant immunoglobulin, etc., can solve problems such as breakthrough and tumor regression

Pending Publication Date: 2022-01-11
GLAXOSMITHKLINE INTPROP +1
View PDF50 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

A major hurdle faced by scientists and clinicians in developing various types of cancer immunotherapies is breaking tolerance to self-antigens (cancer) in order to elicit a robust anti-tumor response leading to tumor regression

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Belantamab mafodotin in combination with pembrolizumab for treating cancer
  • Belantamab mafodotin in combination with pembrolizumab for treating cancer
  • Belantamab mafodotin in combination with pembrolizumab for treating cancer

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0531] Example 1. Production of BCMA antigen binding proteins.

[0532] Production of antigen binding proteins according to the invention and conjugation to toxins as described herein and the respective binding affinities of such antigen binding proteins can be found in WO2012163805, as incorporated herein by reference.

Embodiment 2

[0533] Example 2 - Immunogenic Cell Death (ICD)

[0534] The process of immunogenic cell death can induce the production of dangerous molecules that lead to dendritic cell activation (see Figure 1A - ICD is a specific type of apoptosis that is often associated with cellular release of ATP and HMGB1 and exposure of CRT at the cell membrane. ICDs induce immune responses by participating in the process of antigen presentation by dendritic cells (DCs). NCI-H929 cells treated with BCMA ADC (anti-BCMA antibody conjugated with MMAF: GSK2857916) produced three dangerous molecules (ATP, HMGB1 and CRT) after cell killing ( Figure 1B - Tested cell lines were treated with anti-BCMA-MMAF antibody drug conjugate or mitoxantrone for 48 hours and then evaluated for: 1) loss of cell number by automated flow cytometry, 2) polyclonal Anti-CRT antibody labeling and assessment of calreticulin (CRT) exposure by flow cytometry, 3) assessment of HMGB1 content in cell supernatants by ELISA followe...

Embodiment 3

[0544] T cells can be activated by engagement of T cell receptors (TCRs) expressed on the cell surface and co-stimulatory molecules. A number of additional surface markers are upregulated following T cell activation. The in vitro effects of BCMA ADC (anti-BCMA antibody conjugated to MMAF: GSK2857916) on T cell activation and function were characterized by monitoring many of these T cell activation related markers. Furthermore, upon activation, T cells produce cytokines such as IFNγ and IL-4. The effect of BCMA ADCs on IFNγ and IL-4 production in stimulated T cells was also investigated. These experiments can provide data on the effects of BCMA ADCs on T cell activation and function. In addition, the proliferation of human CD4+ and CD8+ T cells after stimulation in the presence of BCMA ADC was also assessed. Human blood was obtained from GlaxoSmithKline's blood donor procurement program. Peripheral blood mononuclear cells (PBMC) were isolated from human whole blood by Ficol...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
affinityaaaaaaaaaa
affinityaaaaaaaaaa
molecular weightaaaaaaaaaa
Login to View More

Abstract

Disclosed herein are combinations of an antigen binding protein that binds BCMA with an antigen binding protein that bind to an immunomodulatory agents, such as PD-1 or OX40, pharmaceutical compositions thereof, uses thereof, and methods of treatment comprising administering the combinations, including uses in cancer.

Description

[0001] sequence listing [0002] This application contains a Sequence Listing that has been filed electronically in ASCII format and is hereby incorporated by reference in its entirety. [0003] field of invention [0004] The present invention relates to combination products comprising anti-BCMA antigen binding proteins (including monoclonal antibodies against human BCMA) in combination with immunomodulators such as anti-PD-1 antigen binding agents and / or anti-OX40 antigen binding proteins. Furthermore, the present invention relates to the use of a combination product in the treatment of cancer in mammals such as humans. [0005] Background of the invention [0006] Effective treatment of hyperproliferative diseases, including cancer, is an ongoing goal in the field of oncology. In general, cancer results from the deregulation of normal processes controlling cell division, differentiation, and apoptotic cell death, and is characterized by the proliferation of malignant cells...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07K16/28A61P35/00A61K39/395
CPCA61K2039/507C07K16/2818C07K16/2878A61P35/00A61K2039/545A61K47/6849C07K2317/24C07K2317/75A61K39/3955A61K47/68031A61K2300/00
Inventor J·奥帕林斯卡
Owner GLAXOSMITHKLINE INTPROP
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com